Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis

Abstract

Our data indicate that urinary proteome analysis has the potential to identify various types of CKD defined by pathological assessment of renal biopsies and current clinical practice in general. Moreover, these approaches may provide information to model molecular changes per CKD.

The role of mass spectrometry in studies of glycation processes and diabetes management

“…Moreover, another advantage of using urine, instead of blood, is its easy and non‐invasive collection that allows repeated sampling for disease monitoring. In the last years, several studies have been performed, in urines, aiming to identify biomarkers that can detect early stages of DN and progressive kidney function decline in diabetic patients, as well as biomarkers that can allow for a non‐invasive diagnosis of kidney disease (Chang et al ., ; Chu et al ., ; Manwaring et al ., ; Merchant et al ., ; Lewandowicz et al ., ; Siwy et al ., ; Vitova et al ., ; Wheelock et al ., ).…”

“…Siwy et al . () by using CE–MS aimed to verify if urinary proteome analysis holds information on disease etiology and allows to discriminate among seven different types of CKD that in the current clinical practice are defined by pathological assessment of renal biopsies. Totally, 1180 urine samples from CKD patients have been analyzed (706 samples for the discovery and 474 samples for the independent validation).…”

“…Moreover, another advantage of using urine, instead of blood, is its easy and non-invasive collection that allows repeated sampling for disease monitoring. In the last years, several studies have been performed, in urines, aiming to identify biomarkers that can detect early stages of DN and progressive kidney function decline in diabetic patients, as well as biomarkers that can allow for a non-invasive diagnosis of kidney disease (Chang et al, 2017;Chu et al, 2013;Manwaring et al, 2013;Merchant et al, 2013;Lewandowicz et al, 2015;Siwy et al, 2017;Vitova et al, 2017;Wheelock et al, 2017). Siwy et al (2017) by using CE-MS aimed to verify if urinary proteome analysis holds information on disease etiology and allows to discriminate among seven different types of CKD that in the current clinical practice are defined by pathological assessment of renal biopsies.…”

Diagnostic and prognostic tests in systemic lupus erythematosus

“…Over the past 5 years, capillary electrophoresis (CE) coupled to MS (CE-MS) has been the predominant proteomic technique used in the study of urinary biomarkers for the diagnosis and prognosis of chronic kidney disease (CKD), including LN [73]. Aside from providing higher resolution, this approach termed “peptidomics” is also considered robust, inexpensive, and reproducible [74]. …”

“…Since CE-MS enabled discrimination between patients with and without CKD [77], a subsequent study was conducted using this same technology to assess the value of the urinary proteome for the noninvasive discrimination of various types of CKD from 7 different etiologies, including LN [74]. Using datasets from a large cohort of 1180 individuals with CKD, 287 disease-specific biomarkers were defined.…”